The 'Self-Destruct' Fat Shot Billed as Obesity Medicine Faces Its Pivotal Trial Below the Obesity Line

Can you actually get rid of a fat cell? For years I’ve carried a slightly bleak answer: mostly no. Diet, exercise and Ozempic all shrink fat cells, but your adult body holds the total count remarkably steady, a population of deflated cells waiting patiently to be refilled. So when a headline this week promised an injection that makes fat cells self-destruct, and hinted it might stop weight flooding back after people quit GLP-1 drugs, my first question was a dull one. Who is this drug actually being tested in?

The answer surprised me. The drug is CBL-514, from Caliway Biopharmaceuticals of New Taipei City, Taiwan, and its pivotal phase 3 study, SUPREME-02, plans to enroll about 320 adults with a BMI above 18.5 and below 30, which is where obesity begins on the standard scale. It shuts out anyone currently on a GLP-1 drug or in a weight-loss program, along with anyone carrying severe visceral fat, and to get in you have to be dissatisfied with your belly. The primary endpoint is a composite: at least a two-grade improvement on a five-point abdominal-fat scale that participants rate themselves, plus an MRI-confirmed fat reduction, measured four weeks after the last of up to four treatments. Neither body weight nor visceral fat appears anywhere among its outcomes.

That’s a belly-contouring trial. Meanwhile, at the European Association for the Study of Diabetes meeting in Milan, CBL-514 was presented by Caliway’s Yu-Fang Ling and W. Timothy Garvey of the University of Alabama at Birmingham, and Garvey called it “a highly innovative approach to obesity pharmacotherapy that has produced some remarkable results.” HCPLive’s write-up printed no financial disclosures for him, though his statement for a January 2026 UAB lecture series is public. Garvey has disclosed research support and consulting fees from Novo Nordisk, maker of Wegovy, and stock in Eli Lilly, maker of Zepbound. The same statement lists stock in Pfizer, Novartis, Bristol-Myers Squibb and Merck. Nothing in the coverage ties him financially to Caliway, and none of this proves anything about how he reads the data. But Caliway is building CBL-514 as an add-on to Zepbound rather than a rival to it, and readers should have seen those ties printed beside the praise.

Some of what the shot did is impressive. In two phase 2 trials, CBL-514 was injected into the fat under the skin of the lower abdomen in adults with a BMI between 22 and 30, up to 600 mg every three weeks for up to 12 weeks. At eight weeks, 69.6% of treated participants had lost at least 150 mL of that subcutaneous fat, about two-thirds of a cup, and no one on placebo had. Caliway says the drug triggers apoptosis, the cell’s own tidy self-dismantling program, in fat cells while sparing the tissue around them. The company reports more than 544 people dosed across its trials, mostly mild-to-moderate redness, swelling and pain at the injection site, and no serious adverse events in these studies.

The EASD headline, though, was visceral fat, the deeper fat packed around your liver and gut and the kind tied to metabolic disease. In an MRI subgroup of 41 people (23 on the drug, 18 on placebo), visceral fat fell 12.01% on CBL-514 four weeks after the last injection and rose 5.68% on placebo. At the later check, eight or twelve weeks out depending on the trial, the drug group sat 10.45% below baseline and the placebo group 11.76% above it, a 22.21-point gap.

Here’s where I stopped and reread. Visceral fat doesn’t sit under your skin; it lives inside the abdominal cavity, behind a wall of muscle, draped around your organs. CBL-514 goes into the subcutaneous layer on the outside of that wall. So how does a shot into the outer layer shrink fat on the far side of the muscle? Does some of the drug reach the circulation? Does the body reshuffle its fat stores once the outer layer is depleted? Neither Caliway’s release nor the conference coverage offers an explanation. Justin Rochford of the University of Aberdeen told the UK’s Science Media Centre that “it will be very important to show what happens to fat in the liver, circulating fats in the blood.” A drug sold on precision ought to be able to tell us where it goes.

Then there’s the placebo arm, where the result starts to wobble. These were adults with a BMI between 22 and 30 getting saltwater injections, and in Caliway’s figures their visceral fat grew 11.76% within weeks. HCPLive describes a different cut of the data: 46 people, restricted to those whose body weight changed by less than 6.61 pounds, with placebo visceral fat up 18.4% at weeks 8 to 12 and the drug group down 7.3%. The two analyses don’t use the same population, so their numbers needn’t match, but they share a pattern, because in both more than half of the gap between the arms comes from the placebo group gaining visceral fat rather than the drug group losing it. Nobody has explained why adults on saltwater, in one cut screened for barely changing weight, would add that much visceral fat in about three months, and there is no full paper to check. Rochford also noted that the study “is also quite small and doesn’t say whether men or women were studied.”

The fat-cell idea itself is new territory for obesity drugs, and it rests on a 2008 Nature study that still delights me. Kirsty Spalding, Jonas Frisén, Peter Arner and colleagues dated human fat cells using carbon-14 left over from Cold War nuclear tests and found that about 10% of fat cells are renewed every year, while the total “stays constant in adulthood in lean and obese and even under extreme conditions.” Your body keeps a census, replacing the dead one by one. Today’s weight-loss drugs shrink the cells in that census, and Caliway’s hypothesis is that removing some of them leaves less storage space to refill.

The GLP-1 data show why that’s an attractive bet. In the STEP 1 extension, a Novo Nordisk-funded follow-up of 327 people, participants lost 17.3% of their body weight on semaglutide over 68 weeks, and a year after stopping they had regained 11.6 percentage points, leaving them only 5.6% below where they started. Roughly two-thirds came back. Whether surviving, shrunken fat cells drive that rebound hasn’t been established, and Caliway’s evidence that CBL-514 can blunt it comes from rats, which lost more weight on CBL-514 plus tirzepatide than on tirzepatide alone and regained less once tirzepatide was withdrawn.

Surgeons have tried subtracting fat cells before. In 2011 Teri Hernandez, Robert Eckel and colleagues at the University of Colorado ran what was described as the first randomized controlled trial of liposuction in humans, and the fat came back within a year, mainly to the upper abdomen, with more around the shoulders and triceps. “We must emphasize that liposuction surgery is not a weight loss procedure,” Hernandez said. A chemical isn’t a cannula, and nobody knows yet whether CBL-514 behaves the same way, but I’d want proof that the fat doesn’t simply move to a new address, especially when visceral fat is a worse one.

Caliway does have an obesity-adjacent study coming. After filing with the FDA in December 2025, the company announced on August 25, 2026 that the agency had cleared CBL-0201WR, a phase 2 trial pairing CBL-514 with Zepbound in about 120 overweight or obese adults in the U.S. Even there, the release describes MRI measurement of abdominal subcutaneous fat volume, while body weight, visceral fat and lean body mass are named only as exploratory endpoints. A separate 250-person phase 2b, built around long-term re-treatment, keeps the BMI-under-30 ceiling and grades abdominal fat by MRI four weeks after the final treatment.

At every stage, then, the thing being measured is a flatter stomach, and Garvey said nearly as much: “We expect that patients will be pleased by the cosmetic effects, such as the flatter stomach.” I have no quarrel with a needle-based alternative to liposuction for a stubborn belly. But that’s a cosmetic product, and it reached the public dressed as obesity pharmacotherapy. Marie Spreckley of the University of Cambridge, who reports no industry funding for her research, drew the line plainly in the same Science Media Centre roundup: “These human findings do not establish whether the treatment helps people lose weight or improves their health.”

The question worth paying for is simple to state. Weigh people a year after they stop a GLP-1, with and without CBL-514, and see who’s heavier. No published human data answer it yet, and until they do, I wouldn’t pay to have my fat cells killed on the promise that it keeps the weight off.

Sources

1. Caliway Biopharmaceuticals: EASD press release on CBL-514 subcutaneous and visceral fat data (2026)
2. ClinicalTrials.gov: SUPREME-02, Phase 3 trial of CBL-514 for abdominal subcutaneous fat (NCT07526974)
3. HCPLive: New injectable substantially reduces visceral adipose tissue in obesity
4. Caliway via Placera: CBL-514 combination therapy cleared by U.S. FDA for Phase 2 trial (August 2026)
5. ScienceDaily: New injection makes fat cells self-destruct (October 2026)
6. ClinicalTrials.gov: CBL-514 Phase 2b abdominal fat study with long-term re-treatment (NCT07608757)
7. Science Media Centre: Expert reaction to CBL-514 visceral fat abstract
8. Diabetes, Obesity and Metabolism: Wilding et al., STEP 1 trial extension (2022)
9. Nature: Spalding et al., Dynamics of fat cell turnover in humans (2008)
10. ScienceDaily: Hernandez, Eckel et al., fat returns after liposuction (2011)
11. Pharma Focus Asia: Caliway completes FDA IND submission for Phase 2 CBL-514 study with GLP-1RA therapies (December 2025)
12. UAB Diabetes Research Center: Diabetes Plenary Lecture flyer with financial disclosures (January 2026)